The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center.
FDA expands orphan drug designation for Roswell Park’s brain cancer immunotherapy
- Post author:
- Post published:June 25, 2024
- Post category:uncategorized